ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ADAG vs ORMP // ALTMAN Z-SCORE & DEBT/EQUITY

Adagene Inc. (NASDAQ) VS. Oramed Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ADAG 2 — ORMP 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADAG VS. ORMP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ADAG ORMP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 0.70% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -7.80% -27.20 ORMP /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -8.85% -5.20% -3.65 ORMP /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% 3.80% -63.80 ORMP /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 3/9 +2.00 ADAG /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.5 40.6 +2.90 ADAG /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $165.8M $171.0M -$5.2M ORMP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ADAG REV ORMP REV ADAG GROSS % ORMP GROSS % ADAG FCF ORMP FCF
FY 2025 $7.7M $2.0M — 0.7% -$15.7M -$9.2M
FY 2024 $103.2K $0 — — -$29.7M -$8.4M
FY 2023 $18.1M $1.3M — — -$28.5M -$10.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADAG // BETA —
ORMP // BETA —